Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gabriel Graeff"'
Autor:
Fredi Alexander Diaz-Quijano, Denise Siqueira de Carvalho, Sonia Mara Raboni, Silvia Emiko Shimakura, Angela Maron de Mello, Magda Clara Vieira da Costa-Ribeiro, Lineu Silva, Marilene da Cruz Magalhães Buffon, Eliane Mara Cesario Pereira Maluf, Gabriel Graeff, Gustavo Almeida, Clara Preto, Karin Regina Luhm
Publikováno v:
The Lancet Regional Health. Americas, Vol 35, Iss , Pp 100777- (2024)
Summary: Background: CYD-TDV (Dengvaxia®) was the first dengue vaccine approved, launched in Brazil in 2015 for individuals aged 9–44 years. We aimed to estimate the effectiveness of CYD-TDV in preventing symptomatic dengue cases during a campaign
Externí odkaz:
https://doaj.org/article/ac2fedc759ed417292a1a8a319a96cfa
Autor:
Eliane Cezario Maluf, Elias Teixeira Krainski, Allan A. Evans, Gabriel Graeff, Angela Maron de Mello, Gabriela Amanda de Sousa, Fredi Alexander Diaz Quijano, Clara Preto, Lineu Roberto da Silva, Magda Clara Vieira da Costa-Ribeiro, Denise Siqueira de Carvalho, Marilene da Cruz Magalhães Buffon, Karin Regina Luhm, Sonia Mara Raboni, Silvia Emiko Shimakura
Publikováno v:
SSRN Electronic Journal.
Background: Dengue has shown an increased global incidence and substantial socioeconomic impact in tropical and subtropical countries. The only vaccine currently approved for dengue prevention, Dengvaxia® was administered at the population level in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94fa006e56bd899a5fec96c69a0878a4
https://doi.org/10.2139/ssrn.3899115
https://doi.org/10.2139/ssrn.3899115
Autor:
Karin Regina Luhm, Marilene da Cruz Magalhães Buffon, Eliane Mara Cesário Pereira Maluf, Gabriela Amanda de Sousa, Magda Clara Vieira da Costa-Ribeiro, Elias Teixeira Krainski, Lineu Roberto da Silva, Denise Siqueira de Carvalho, Gabriel Graeff, Sonia Mara Raboni, Clara Preto, Angela Maron de Mello, Silvia Emiko Shimakura
Publikováno v:
Vaccine. 39(4)
The success of vaccination programs depends on the level of acceptance of the vaccine to achieve high vaccine coverage rates (VCR). Vaccine hesitancy is a challenge, especially concerning new vaccines. Dengue vaccine, Dengvaxia®, was licensed in Bra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cba74c387683fef8decc4062707dbca6
https://pubmed.ncbi.nlm.nih.gov/33386178
https://pubmed.ncbi.nlm.nih.gov/33386178